Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.50−0.17 (-1.59%)
Close on Nov 18, 2026Market cap $8.38BP/E –Yield –
Summit Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Summit Therapeutics's total assets was $752.19M at Jun 30, 2026. For fiscal 2025 it was $751.18M, up 72.5% from the year before. The highest annual figure on record is $751.18M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $751.18M | +72.5% |
| FY2024 | Dec 31, 2024 | $435.56M | +114.6% |
| FY2023 | Dec 31, 2023 | $202.95M | -69.4% |
| FY2022 | Dec 31, 2022 | $664.17M | +485.8% |
| FY2021 | Dec 31, 2021 | $113.37M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $752.19M | +132.1% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $647.86M | +68.8% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $751.18M | +72.5% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $261.73M | -48.0% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $324.04M | -5.2% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $383.82M | +117.1% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $435.56M | +114.6% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $502.85M | +130.2% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $341.86M | +44.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $176.78M | -30.6% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $202.95M | -69.4% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $218.48M | +40.7% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $237.37M | +148.0% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $254.90M | +118.8% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $664.17M | +485.8% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $155.33M | +20.7% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $95.72M | -34.2% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $116.47M | -17.3% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $113.37M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $128.67M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $145.52M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $140.79M | – |
See a number that looks wrong?